Sixty metastatic and recurrent breast cancer patients who had been giv
en cyclophosphamide, methotrexate and fluorouracil (CMF) therapy previ
ously and were treated at the Oncology Departments of Cukurova and Ege
University Medical Schools between March 1992-94, were randomized int
o 2 groups for the chemotherapy program, The 30 patients in the Ist gr
oup were given etoposide: 200 mg x day x 5 days orally every 3 weeks.
The 30 patients of the 2nd group were given fluorouracil: 500 mg x m(2
), doxorubicin: 50mg/m(2), cyclophosphamide: 500 mg/m(2) intravenously
every 3 weeks, The response rates were 21/30 in group 1 and 17/30 in
group 2. The median duration of responses was 11 months (8-21) in the
Ist and 3 months (4-18) in the 2nd group. Severe myelotoxicity was obs
erved in 2 of the patients in the Ist group and in 5 of the patients i
n the 2nd group.